加载中
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
常规交易时段
US$2.145
−US$0.035 · -1.61%
盘中时间采用ET。市场数据可能有所延迟。
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
日内区间
当前US$2.145
52周区间
当前US$2.145
盘中时间采用ET。市场数据可能有所延迟。
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
日内区间
当前US$2.145
52周区间
当前US$2.145
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 664.6万 USD | 1363.1万 USD | 6353.3万 USD | 9630万 USD | 5584.6万 USD |
| 销货成本 | 1290.1万 USD | 1.19亿 USD | 1.57亿 USD | 1375.8万 USD | 585万 USD |
| 毛利 | −625.5万 USD | −1.05亿 USD | −9365.4万 USD | 8254.2万 USD | 4999.6万 USD |
| 研究与开发 | 1.08亿 USD | 1.35亿 USD | 1.73亿 USD | 3.2亿 USD | 2.16亿 USD |
| 销售、一般及管理费用 | 4652.1万 USD | 9063.9万 USD | 9685.7万 USD | 8423.2万 USD | 5732.1万 USD |
| 营业费用 | 1.41亿 USD | 1.05亿 USD | 9685.7万 USD | 3.91亿 USD | 2.67亿 USD |
| 利息收入 | 1105.2万 USD | 1728.8万 USD | 1718.6万 USD | 584.2万 USD | 130.9万 USD |
| 折旧和摊销 | 929.5万 USD | 1896.2万 USD | 1828.2万 USD | 1375.8万 USD | 585万 USD |
| 营业利润 | −1.48亿 USD | −2.1亿 USD | −1.91亿 USD | −3.08亿 USD | −2.17亿 USD |
| 净利润 | −1.36亿 USD | −1.86亿 USD | −1.61亿 USD | −2.82亿 USD | −2.12亿 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$5.63
上涨空间 162.47%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI763.46万0.00%2.3万亿 USD0.03%US$381.8-0.04%
Vanguard Extended Market ETFVXF286.76万0.00%954亿 USD0.05%US$234.2-0.34%
Schwab U.S. Small-Cap ETFSCHA117.66万0.01%218.24亿 USD0.03%US$32.755-0.11%
iShares Micro-Cap ETFIWC78.23万0.06%13.17亿 USD0.60%US$182.23-0.42%
Vanguard Health Care ETFVHT67.94万0.00%220亿 USD0.09%US$319.62+0.19%
Invesco RAFI US 1500 Small-Mid ETFPRFZ52.99万0.02%26.7亿 USD0.36%US$53.03-0.24%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM40万0.34%1.17亿 USD0.73%US$15.86-0.50%
Avantis U.S. Small Cap Equity ETFAVSC32.21万0.01%30.82亿 USD0.25%US$70.21+0.33%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTInvesco RAFI US 1500 Small-Mid ETFPRFZEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
